Neuroscience
Congress Materials – World Federation of Societies of Biological Psychiatry (WFSBP 2025)
2025 World Federation of Societies of Biological Psychiatry | Sep 9-12 | Berlin, Germany
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Efficacy of Lumateperone 42 mg in the Treatment of Major Depressive Disorder: A Pooled Analysis of Phase 3 Randomized Controlled Trials
Suresh Durgam, Willie R. Earley, Susan G. Kozauer, Changzheng Chen, John B. Edwards, Rakesh Jain
Long-Term Adjunctive Lumateperone Treatment in Major Depressive Disorder: Results From a Six-Month Open-Label Extension Study
Suresh Durgam, Willie R. Earley, Susan G. Kozauer, Changzheng Chen, Tobie Escher, Andrew J. Cutler
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.
Connect with us
Connect with us
Would you like to clear and leave your conversation? Message history will be lost.